home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

BeiGene's Tislelizumab/Chemo Combo Hits Primary Goal In Gastric Cancer Study ↗

April 20, 2023

Via Benzinga

BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

April 20, 2023

From BeiGene

Via Business Wire

7 Biotech Stocks That Could Cure Your Portfolio Woes ↗

April 19, 2023

If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.

Via InvestorPlace

BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

April 17, 2023

From BeiGene, Ltd.

Via Business Wire

Why BeiGene Stock Jumped Thursday ↗

April 06, 2023

A collaboration deal helped send the Chinese biotech stock higher.

Via The Motley Fool

Beigene Ltd. (NASDAQ: BGNE) Highlighted for Surprising Price Action

April 06, 2023

Via Investor Brand Network

SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

April 17, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

April 17, 2023

From BeiGene

Via Business Wire

BeiGene Earnings Perspective: Return On Capital Employed ↗

March 02, 2023

Via Benzinga

4 Analysts Have This to Say About BeiGene ↗

January 20, 2023

Via Benzinga

FDA Approves BeiGene's Brukinsa For Chronic Lymphocytic Leukemia ↗

January 20, 2023

Via Benzinga

MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

April 17, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials ↗

April 13, 2023

This month, H.C. Wainwright & Co.

Via Benzinga

BeiGene Expands Presence in Latin America With Opening of Brazil Office

April 13, 2023

From BeiGene

Via Business Wire

Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow ↗

April 11, 2023

A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global...

Via Benzinga

Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors ↗

April 11, 2023

This month, Enlivex Therapeutics Ltd.

Via Benzinga

BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity

March 30, 2023

From BeiGene

Via Business Wire

BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey

March 21, 2023

From BeiGene

Via Business Wire

Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken ↗

March 13, 2023

Some Asian firms have disclosed cash deposits at troubled U.S. lender Silicon Valley Bank (NASDAQ: SIVB), known for its deep ties with the healthcare and tech sector. Most emphasized that the amounts...

Via Benzinga

BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results

February 27, 2023

From BeiGene, Ltd.

Via Business Wire

Nasdaq, S&P 500 Futures Rebound In New Trading Week But Rising Bond Yields Remain A Risk ↗

February 27, 2023

US stocks are coming off a lackluster week and early indications suggest a reversal in sentiment in the new trading week. While rising bond yields could be a cause of concern, the recent weakness could...

Via Benzinga

Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca ↗

February 25, 2023

Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between...

Via Talk Markets

BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China

February 24, 2023

From BeiGene

Via Business Wire

BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference

February 24, 2023

From BeiGene

Via Business Wire

Five Best And Worst Performing Healthcare Stocks In January 2023 ↗

February 05, 2023

After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and...

Via Talk Markets

New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care

February 03, 2023

From BeiGene

Via Business Wire

BeiGene to Present at Upcoming Investor Conferences

February 01, 2023

From BeiGene

Via Business Wire

Is Johnson & Johnson Still a Good Dividend Stock to Buy? ↗

January 26, 2023

A disappointing fourth-quarter performance has some investors worried about the giant healthcare conglomerate's outlook.

Via The Motley Fool

Five Best And Worst Performing Healthcare Stocks In December 2022 ↗

January 22, 2023

Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst...

Via Talk Markets

Draganfly To Rally Around 87%? Here Are 10 Other Analyst Forecasts For Friday ↗

January 20, 2023

SVB Leerink raised the price target for BeiGene, Ltd. (NASDAQ: BGNE) from $236 to $300. SVB Leerink analyst Andrew Berens maintained an Outperform rating. BeiGene shares rose 2% to $279.90 in...

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com